一般社団法人JBCRG学会発表
2020年
A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study
Yutaka Yamamoto, Hiroji Iwata, Taira Naruto, Norikazu Masuda, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Fumikata Hara, Shigehira Saji, Satoshi Morita, Masakazu Toi, Shinji Ohno, Japan Breast Cancer Research Group.
2020.12 SABCS Oral WEB
Influence of the adjuvant hormonal therapy on hormone sensitivity and survival outcomes in ER+ and HER2−advanced breast cancer: a subgroup analysis of the JBCRG-C06 Safari study
Takahiro Nakayama, Hidetoshi Kawaguchi, Norikazu Masuda, Shigehira Saji, Yutaka Yamamoto, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Miki Yamaguchi, Hiroko Yamashita, Toshinari Yamashita, Daisuke Yotsumoto, Satoshi Morita, Masakazu Toi, Shinji Ohno
2020年10月 第28回日本乳癌学会学術総会 ポスター WEB
A randomized, multicenter, phase II study evaluating the efficacy of interventional maintenance endocrine therapy with Bevacizumab following fixed cycles of Bevacizumab plus Paclitaxel in advanced/metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 BOOSTER trial
Shoichiro Ohtani, Shigehira Saji, Yoshie Hasegawa, Tomomi Fujisawa, Masahiro Kashiwaba, Takanori Ishida, Yutaka Yamamoto, Takashi Ishikawa, Shigenori Nagai, Hiroshi Yoshibayasi, Koji Matsumoto, Yasuaki Sagara, Masahiro Kitada, Toshimi Takano, Masahiro Takada, Norikazu Masuda, Naruto Taira, Satoshi Morita, Shinji Ohno, Masakazu Toi
2020年10月 第28回日本乳癌学会学術総会 口演 WEB
乳癌術前化学療法におけるアブラキサンの有用性についての大規模統合解析 (JBCRG-S01)
二村 学, 大庭真梨, 増田慎三, 中山貴寛, 櫻井健一, 坂東裕子, 岡田守人, 山本 豊, 金 敬徳, 佐伯俊昭, 長嶋 健 桑山隆志, 唐 宇飛, 平野 明, 井口雅史, 山神和彦, 水野 豊, 小島康幸, 八十島宏行, 大野真司
2020年10月 第28回日本乳癌学会学術総会 ポスター WEB
Outcomes of fulvestrant treatment in ER-positive HER2-positive advanced or metastatic breast cancer
Misato Masuyama, Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Koji Kaneko, Shigehira Saji, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Tomomi Fujisawa, Miki Yamaguchi, Toshinari Yamashita, Yutaka Yamamoto, Satoshi Morita, Masakazu Toi, Shinji Ohno
2020年10月 第28回日本乳癌学会学術総会 ポスター WEB
Factors associated with prolonged OS in postmenopausal ER-positive advanced breast cancer patients
Koji Kaneko, Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Shigehira Saji, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Tomomi Fujisawa, Miki Yamaguchi, Toshinari Yamashita, Yutaka Yamamoto, Satoshi Morita, Masakazu Toi, Shinji Ohno
2020年10月 第28回日本乳癌学会学術総会 ポスター WEB
Pooled-analysis of prospective observational studies evaluated the effectiveness and safety of bevacizumab and paclitaxel as the first-line chemotherapy for HER2-negative metastatic breast cancer.
Yutaka Yamamoto, Hiroyasu Yamashiro, Andreas Schneeweiss, Volkmar Müller, Oleg Gluz, Peter Klare, Bahriye Aktas, Dank Magdolna, László Büdi, Béla Pikó, László Mangel, Masakazu Toi, Satoshi Morita, Shinji Ohno
2020年10月 第28回日本乳癌学会学術総会 口演 WEB
A randomized, phase 2 study of neoadjuvant chemotherapy containing eribulin mesylate for triple-negative primary breast cancer patients stratified by homologous recombination deficiency status (JBCRG-22)
Hiroko Bando, Norikazu Masuda, Takashi Yamanaka, Takayuki Kadoya, Masato Takahashi, Shigenori Nagai, Shoichiro Ohtani, Tomoyuki Aruga, Eiji Suzuki, Yuichiro Kikawa, Hiroyuki Yasojima, Hiroi Kasai, Hiroshi Ishiguro, Hidetaka Kawabata, Satoshi Morita, Hironori Haga, Tatsuki R.Kataoka, Ryuji Uozumi, Shinji Ohno, Masakazu Toi
2020.9 ESMO Oral WEB
Patient-reported outcomes of a switch to maintenance endocrine therapy following induction chemotherapy versus continuation of chemotherapy in ER-positive HER2-negative metastatic breast cancer: a randomized, open-label, phase 2 clinical trial
Shigehira Saji, Naruto Taira, Satoshi Morita, Masahiro Kitada, Toshimi Takano, Masahiro Takada, Tohru Ohtake, Tatsuya Toyama, Yuichiro Kikawa, Yoshie Hasegawa, Tomomi Fujisawa, Masahiro Kashiwaba, Takanori Ishida, Rikiya Nakamura, Yutaka Yamamoto, Uhi Toh, Hiroji Iwata, Norikazu Masuda, Shinji Ohno and Masakazu Toi
2020.9 ESMO Poster WEB
Pooled-analysis of prospective observational studies evaluated the effectiveness and safety of bevacizumab and paclitaxel as the first-line chemotherapy for HER2-negative metastatic breast cancer
Hiroyasu Yamashiro, Yutaka Yamamoto, Andreas Schneeweiss, Volkmar Müller, Oleg Gluz, Peter Klare, Bahriye Aktas, Dank Magdolna, László Büdi,Béla Pikó, László Mangel, Masakazu Toi, Satoshi Morita, Shinji Ohno
2020.9 ESMO Poster WEB